Longevity
Female aging biology, biomarkers, and the clinics, research centers, and capital rebuilding longevity around female physiology.
ŌURA raises over $900M at ~$11B valuation, led by Fidelity
Tally Health publishes CheekAge — next-gen buccal epigenetic clock in GeroScience
TruDiagnostic awarded NIH SBIR grant to build W-Function Epigenomic Roadmap
Signals in Longevity
- Product Launch ↗Product Launch · May 1Oura launches hormonal birth-control support & menopause insights, closing wearable data gap for womenThe Index Editorial
- Funding ↗
- Policy ↗Policy · Oct 7TruDiagnostic awarded NIH SBIR grant to build W-Function Epigenomic RoadmapThe Index Editorial
- Policy ↗Policy · Jun 20NIH ORWH announces intramural innovation grants for women's midlife health researchThe Index Editorial
- Product Launch ↗Product Launch · May 27Midi Health launches AgeWell — first insurance-covered longevity program for womenThe Index Editorial
- Funding ↗Funding · Apr 22Superpower raises $30M Series A and publicly launches 'world's first health super app'The Index Editorial
Top organizations in Longevity
Buck Institute (Female Aging Program)
Research InstituteAging biology research with a dedicated female-physiology track.
Women's Health Collective
OperatorOperator network convening founders and clinical leaders.
Global Women's Health Summit
ConferenceAnnual gathering of operators, clinicians, and investors.
ŌURA
StartupSmart ring for health, sleep, menstrual & pregnancy tracking; ~$11B valuation.
Whoop
StartupWearable for fitness, recovery, and metabolic-signal tracking.
TruDiagnostic
StartupTruAge™ / TruHealth™ at-home epigenetic DNA-methylation tests; 2025 NIH SBIR for W-Function Epigenomic Roadmap for women's healthspan.
Market maps · Longevity
Recent analysis · Longevity
The cultural turn toward longevity is changing what women buy, how they screen, and how they relate to clinicians.
The Index Editorial·
GeroScience publication: Tally Health's CheekAge predicts all-cause mortality and tracks with lifestyle factors via cheek-swab DNA methylation.
The Index Editorial·JAMA 2024 review synthesizes 20+ years of WHI follow-up: in the timing-hypothesis window (<10 yrs from menopause or <60), MHT shows no significant rise in all-cause mortality and a possible benefit for estrogen-alone in younger women.
The Index Editorial·
Analysts covering Longevity
Get the Longevity briefing weekly.
A focused read on what's moving in longevity — financings, research, regulatory shifts, and ecosystem moves.